Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Star Combo PharmaASX:S66 20 Debt-to-EBITDA is 2.75 as of Jun. 2026, which is 1000% above its 10-year median of 0.25. GuruFocus rates ASX:S66 with a GF Score™ of 20/100 and a GF Value™ of A$0.13 (Fairly Valued). The stock has 4 warning signs investors should review. Among 1,571 Consumer Packaged Goods companies, Star Combo Pharma ranks better than 52.77% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Star Combo Pharma's Debt-to-EBITDA or its related term are showing as below:
ASX:S66'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -32.45 Med: 0.25 Max: 20.25
Current: 1.9
During the past 10 years, the highest Debt-to-EBITDA Ratio of Star Combo Pharma was 20.25. The lowest was -32.45. And the median was 0.25.
ASX:S66's Debt-to-EBITDA is ranked better than 52.77% of 1571
companies
in the Consumer Packaged Goods industry
Industry Median: 2.11
vs ASX:S66: 1.90
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Star Combo Pharma Debt-to-EBITDA Related Terms
Star Combo Pharma Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Star Combo Pharma's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Household & Personal Products subindustry, Star Combo Pharma's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Star Combo Pharma Debt-to-EBITDA vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Star Combo Pharma's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Star Combo Pharma's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Jun. 2026) EBITDA data.
Star Combo Pharma (ASX:S66) has a Debt-to-EBITDA of 2.75 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Star Combo Pharma. This is 1000% above median its historical median of 0.25. According to the industry distribution chart, Star Combo Pharma ranks #742 out of 1571 companies in the Consumer Packaged Goods industry, placing it in the top 47.2%.
Is Star Combo Pharma's Debt-to-EBITDA too high?
Star Combo Pharma's current Debt-to-EBITDA of 2.75 is 1000% above median its 10-year median of 0.25. The Consumer Packaged Goods industry median Debt-to-EBITDA is 2.11. Star Combo Pharma's value of 2.75 is 30.3% above this industry median. Based on the distribution chart, Star Combo Pharma ranks #742 out of 1571 companies in the Consumer Packaged Goods industry, which is above the industry midpoint. Overall, Star Combo Pharma has a GF Score™ of 20/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Star Combo Pharma's Debt-to-EBITDA compare to PG and CL?
According to the Consumer Packaged Goods industry distribution chart, Star Combo Pharma ranks #742 out of 1571 companies for Debt-to-EBITDA. This puts Star Combo Pharma in the upper half of its industry. The industry median Debt-to-EBITDA is 2.11. Star Combo Pharma's value of 2.75 is 30.3% above this benchmark. While the company's 10-year median is 0.25 vs. the industry median of 2.11, Star Combo Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Consumer Packaged Goods company?
The median Debt-to-EBITDA among Consumer Packaged Goods companies is 2.11, based on 1,571 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Star Combo Pharma's current Debt-to-EBITDA of 2.75 is 30.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Star Combo Pharma. For the Consumer Packaged Goods industry, the median Debt-to-EBITDA is 2.11 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Star Combo Pharma's current Debt-to-EBITDA is 2.75, which is 1000% above median its own 10-year median of 0.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Star Combo Pharma stock overvalued right now?
Based on GuruFocus' analysis, Star Combo Pharma (ASX:S66) is currently considered Fairly Valued. The stock's GF Value™ is A$0.13, compared to a current price of A$0.14 — trading 7.7% above its estimated fair value. The current Debt-to-EBITDA is 2.75, which is 1000% above median its 10-year median of 0.25 and 30.3% above the Consumer Packaged Goods industry median of 2.11. Star Combo Pharma's overall GF Score™ is 20/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Star Combo Pharma (ASX:S66), the current Debt-to-EBITDA is 2.75 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Star Combo Pharma (ASX:S66) Overvalued in 2026?
Based on GuruFocus' analysis, Star Combo Pharma stock appears to be overvalued.
The current stock price of A$0.14 is trading 7.7% above its estimated GF Value™ of A$0.13.
GuruFocus considers Star Combo Pharma to be Fairly Valued.
Key valuation signals for ASX:S66:
Debt-to-EBITDA: 2.75 (1000% above median its 10-year median of 0.25)
GF Value™: A$0.13 vs. price of A$0.14 (7.7% above fair value)
Industry Position: 30.3% above the Consumer Packaged Goods median (#742 of 1571)
No single metric tells the full story. See the ASX:S66 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Star Combo Pharma Ltd is engaged in the manufacturing and distribution of food products and nutritional supplements. The company offers products such as Costar, Living Healthy, Amax, and J&K. It operates in two segments. The Star Combo segment engages in the development, manufacturing, marketing, and sales of natural health supplements and skincare products. The Austoyou retail business segment consists of the Australia-China e-commerce platform that offers product lines directly to Chinese health product consumers, and Koala Mall's two retail stores in Sydney. Geographically, it operates in China and Australia.
20GF Score
Get the complete analysis for ASX:S66
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:S66 has been successfully added to your 
